10-Q: STAAR Surgical Reports Mixed Q1 Results with Revenue Growth Offset by Increased Expenses

STAAR Surgical's first quarter saw a 5.2% increase in net sales, driven by ICL growth, but a net loss due to higher operating expenses.

Summary

• STAAR Surgical reported a net sales increase of 5.2% for the first quarter of 2024, reaching $77.356 million, compared to $73.528 million in the same period of 2023.
• The growth was primarily driven by a 9.2% increase in sales of Implantable Collamer Lenses (ICLs), which totaled $77.151 million.
• Other product sales, including cataract IOLs, decreased significantly by 92.9% to $0.205 million, as the company phases out these products.
• The company experienced a net loss of $3.339 million, or $0.07 per share, compared to a net income of $2.710 million, or $0.06 per share, in the first quarter of 2023.
• Operating expenses increased significantly, with general and administrative expenses rising by 28.3% and research and development expenses increasing by 29.8%.
• Gross profit increased by 6.0% to $61.035 million, with a gross margin of 78.9%, up from 78.3% in the prior year.
• Cash and cash equivalents increased to $224.024 million, up from $183.038 million at the end of 2023.
• Investments available for sale decreased to $28.088 million from $49.391 million at the end of 2023.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the net loss and increased operating expenses, despite revenue growth. The company's strategic shift away from cataract IOLs also introduces some uncertainty.

Positives

• Net sales increased by 5.2% year-over-year, indicating continued demand for the company's products.
• ICL sales grew by 9.2%, demonstrating the strength of the company's core product.
• Gross profit margin improved to 78.9%, suggesting better cost management and pricing strategies.
• Cash and cash equivalents increased by $40.986 million, providing a strong liquidity position.
• The company is seeing growth in key markets such as India, Japan, China, the US and Canada.

Negatives

• The company reported a net loss of $3.339 million, a significant downturn from the net income of $2.710 million in the same quarter last year.
• Operating expenses increased substantially, with general and administrative expenses up by 28.3% and research and development expenses up by 29.8%.
• Other product sales declined by 92.9%, indicating a significant reduction in revenue from non-ICL products.
• Investments available for sale decreased by $21.303 million, which could impact future investment income.

Risks

• Increased operating expenses could continue to impact profitability if not managed effectively.
• The phase-out of cataract IOLs could lead to a loss of revenue if not fully offset by ICL sales growth.
• Fluctuations in foreign currency exchange rates could negatively impact sales and profitability.
• The company is subject to various legal proceedings and claims, which could lead to financial harm.
• The company's future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of pre-tax income.

Future Outlook

The company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The company's growth strategy includes making its complete ICL product line available in existing geographic markets and expanding into new markets. The company is focused on driving awareness of the ICL procedure and providing surgeon training and support.

Management Comments

• The company's goal is to position its refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses.
• The company employs a commercialization strategy that strives for sustainable profitable growth.
• The company is focused on driving awareness of the ICL procedure and the clinical benefits of our ICLs, and providing surgeon training, support and education, particularly in our newer markets.

Industry Context

The report indicates a continued focus on the refractive surgery market, particularly with the company's ICL product line. The phase-out of cataract IOLs reflects a strategic shift towards its core product. The company's growth in key markets like China, Japan, India, the US and Canada aligns with global trends in ophthalmic surgery.

Comparison to Industry Standards

• While STAAR Surgical experienced a 5.2% increase in net sales, other medical device companies in the ophthalmic space have reported varying results. For example, Alcon reported a 7% increase in net sales in their most recent quarter, while Johnson & Johnson Vision reported a 5.8% increase.
• STAAR's gross margin of 78.9% is relatively high compared to some competitors, such as Alcon which reported a gross margin of 60.8%. This suggests a strong pricing power for STAAR's ICL products.
• The increase in operating expenses for STAAR is a concern, as some competitors have been able to manage their expenses more effectively. For example, Johnson & Johnson Vision reported a 1.2% increase in operating expenses.
• STAAR's focus on ICLs is a differentiator, as many competitors offer a broader range of ophthalmic products. This specialization could be a strength or a weakness depending on market trends.

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, including contractual rights and obligations, employment matters, or claims of product liability.

Stakeholder Impact

• Shareholders may be concerned about the net loss and increased operating expenses.
• Employees may be affected by changes in compensation and benefits.
• Customers will continue to have access to the company's ICL products.
• Suppliers may be impacted by changes in the company's product mix.
• Creditors will be monitoring the company's financial performance.

Next Steps

• The company will continue to focus on growing its ICL business.
• The company will monitor and adjust its effective income tax rate based on changes in tax laws and the geographic composition of its pre-tax income.
• The company will continue to evaluate the disclosure requirements of recent accounting pronouncements.

Key Dates

Keywords

ICL, Implantable Collamer Lenses, Ophthalmic Surgery, Refractive Surgery, Net Sales, Gross Profit, Operating Expenses, Net Loss, Financial Results, Quarterly Report